This study investigates the safety and efficacy of an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed acute myeloid leukemia, showing a 47% complete response rate and improved survival with manageable side effects.
This study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.
This study investigates amivantamab in recurrent/metastatic head and neck cancer, showing a 42% response rate and durable antitumor activity after prior immunotherapy and chemotherapy.
This study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.